Formulation Development of a Nucleotide Phosphoramidate

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-06-02-2003
Volume 27
Issue 6

A small-volume parenteral formulation of NB1011, an enzyme-catalyzed therapeutic activation compound, was successfully developed for intravenous administration.

External Link - article-59281.pdf

Articles in this issue
June 2003
From Genome Exploration to Drug Development
Are you ready for Gen3
Enhancement of the Dissolution Rate and Bioavailability of Glipizide through Cyclodextrin Inclusion Complex
Formulation Development of a Nucleotide Phosphoramidate
Behavior of Uptake of Moisture by Drugs and Excipients under Accelerated Conditions of Temperature and Humidity in the Absence and the Presence of Light
Outsourcing Outlook
Recent Videos
Behind the Headlines, Episode 10
Jens Schmidt, associate director MSAT at Lonza
Related Content
High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Dealmaking on the Rise?

Mike Hennessy Jr.
January 31st 2025
Article

If the conditions prove optimal, 2025 could be a prosperous year for bio/pharma business deals.

Drug Solutions Podcast: Forecasting Pharma’s Future

Drug Solutions Podcast: Forecasting Pharma’s Future

Felicity Thomas
January 31st 2025
Podcast

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

Zentalis to Cut 40% of Workforce Under Strategic Restructuring Plan

Patrick Lavery
January 30th 2025
Article

The reduction is expected to be “substantially completed,” the San Diego-based company said, in the second quarter of 2025.

Drug Solutions Podcast: Realizing AI’s Potential

Drug Solutions Podcast: Realizing AI’s Potential

Felicity Thomas
December 20th 2024
Podcast

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

European Drug Shortage Monitoring Platform Fully Operational

Susan Haigney
January 29th 2025
Article

The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

Lantheus Announces Agreement to Acquire Evergreen Theragnostics

Patrick Lavery
January 28th 2025
Article

The deal is being made for an all-cash price of $250 million, but with an additional $752.5 million available in potential milestone payments.